Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21Cip1 expression and hampers tumour cell growth in vitro and in vivo by Raimondi, L et al.
Inhibition of Notch3 signalling induces
rhabdomyosarcoma cell differentiation promoting p38
phosphorylation and p21
Cip1 expression and hampers
tumour cell growth in vitro and in vivo
L Raimondi
1,10, R Ciarapica
1,10, M De Salvo
1, F Verginelli
1, M Gueguen
2, C Martini
1, L De Sio
1, G Cortese
3, M Locatelli
4, TP Dang
5,
N Carlesso
6, L Miele
7, S Stifani
8, I Limon
2, F Locatelli
1,9 and R Rota*
,1
Rhabdomyosarcoma (RMS) isapaediatricsoft-tissue sarcomaarising fromskeletalmuscleprecursorscoexpressingmarkersof
proliferation and differentiation. Inducers of myogenic differentiation suppress RMS tumourigenic phenotype. The Notch target
gene HES1 is upregulated in RMS and prevents tumour cell differentiation in a Notch-dependent manner. However, Notch
receptors regulating this phenomenon are unknown. In agreement with data in RMS primary tumours, we show here that the
Notch3 receptor is overexpressed in RMS cell lines versus normal myoblasts. Notch3-targeted downregulation in RMS cells
induces hyper-phosphorylation of p38 and Akt essential for myogenesis, resulting in the differentiation of tumour cells into
multinucleated myotubes expressing Myosin Heavy Chain. These phenomena are associated to a marked decrease in HES1
expression, an increase in p21
Cip1 level and the accumulation of RMS cells in the G1 phase. HES1-forced overexpression in RMS
cells reverses, at least in part, the pro-differentiative effects of Notch3 downregulation. Notch3 depletion also reduces the
tumourigenicpotentialofRMScellsbothinvitro andinvivo.Theseresults indicatethat downregulationofNotch3issufﬁcientto
force RMS cells into completing a correct full myogenic program providing evidence that it contributes, partially through HES1
sustained expression, to their malignant phenotype. Moreover, they suggest Notch3 as a novel potential target in human RMS.
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Rhabdomyosarcoma (RMS) is a skeletal muscle-derived
soft-tissue sarcoma affecting children and adolescents.
It accounts for approximately 50% of all paediatric soft-tissue
sarcomas, and for 7–8% of all childhood malignancies.
1
Paediatric RMS includes two major histological subtypes,
embryonal and alveolar. Approximately 70% of alveolar
RMS harbour chromosomal translocations such as t(2;13)
or t(1;13), resulting in PAX3-FKHR or PAX7-FKHR fusion
products, and were considered the most aggressive forms.
By contrast, recent studies demonstrated that fusion-
negative alveolar tumours were molecularly and clinically
indistinguishable from embryonal ones.
2 Despite aggres-
sive treatment, the management of paediatric RMS, especially
the fusion-positive alveolar form, often metastatic at
diagnosis and resistant to conventional therapy, remains
challenging.
Similar to myogenic progenitors, RMS cells express
muscle-differentiating factors but have lost the ability to
terminally differentiate thus proliferating indeﬁnitely.
3 Promot-
ing redifferentiation of RMS to its original skeletal muscle
tissue type is a recognized strategy to suppress transformed
phenotype.
4,5 In this view, gaining of knowledge on pathways
involved in physiological myogenesis and that are found
deregulated in RMS is pivotal for the identiﬁcation of selected
factors sustaining the pro-tumoural phenotype.
Notch proteins have fundamental roles in balancing
proliferation versus differentiation.
6 Mammals harbour four
Notch genes, each encoding a type I transmembrane Notch
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www.nature.com/cddreceptor paralog (Notch1–4). Notch activation begins with the
binding of the extracellular domain of transmembrane ligands
of the Delta and Jagged family to Notch receptors on
neighbouring cells. This interaction allows Notch to undergo
sequential proteolytic cleavages, the last one being mediated
by a g-secretase complex that releases an active Notch intra-
cellular domain (Notch
IC). Notch
IC translocates into the nucleus,
where it activatesthe expression oftargetgenes together with
the DNA-binding RBP-Jk protein (also known as CSL, for
CBF1/Su(H)/Lag1).
7 Among Notch target genes are those
encoding the enhancer of split group of transcriptional repres-
sors, which are termed hairy and enhancer of split (HES) 1–7
a n dH E S - r e l a t e dr e p r e s s o r( H E Y )1 , 2a n dLi nm a m m a l s .
8
Notch activation in muscle progenitors impairs the tran-
scription of myogenic factors, preventing cell differentiation
and promoting proliferation.
9 Consistently, inhibition of
g-secretase activity leads to myoblasts differentiation.
10–12
Recently, Sang et al.
13 have shown that HES1 is upregulated
in primary RMS and its inhibition, as well as the blockade of
g-secretase activity, induces cell cycle arrest and differentiation
of RMS cell lines. Combined with the fact that Notch signalling
modulates critical aspects of cancer progression in many
types of tumours,
14 these data suggested that aberrant Notch
signalling could underlie the development of RMS. However,
the mechanism responsibleforthe anti-differentiative function
of HES1 in RMS remained to be clariﬁed. Here we identify the
Notch3 receptor as a major player in this process. We report
that, in agreement with data on RMS primary tumours,
15
Notch3 is overexpressed and activated in RMS cell lines
compared with their normal counterpart. Moreover, down-
regulationofNotch3inRMScellsinducesinhibitionofG1-to-S
cell cycle progression resulting in skeletal muscle-like
differentiation and the expression of myogenic markers such
as Myosin Heavy Chain (MHC) and troponin. These pro-
cesses follow a marked increase of p38 MAPK (mitogen-
activated protein kinase) phosphorylation and cyclin-depen-
dent kinase (CDK) inhibitor p21
Cip1 expression. HES1 is an
important downstream effector of these phenomena as (i)
HES1levelisnoticeablydecreasedafterNotch3silencingand
(ii) HES1-forced overexpression partly overcomes Notch3
depletion-associated phenotype. Finally, Notch3 silencing in
RMS cells compromises their tumourigenic ability in vitro and
tumour growth in vivo. Taken together, these results provide
evidence for a pro-tumourigenic role of Notch3 signalling
pathway in RMS.
Results
Notch signalling components are transcriptionally deregu-
lated in human RMS cell lines and primary tumours. Two
PAX3-FKHR fusion-positive alveolar (RH30 and RH41) and
three fusion-negative embryonal (RD, RH18 and A204) human
RMS cell lines were characterized for the expression and
activation of Notch components and compared with healthy
primary human skeletal myoblasts (SkMC, control cells).
As reported in Figure 1a, all tumour cell lines had increased
levels of both Notch1 and Notch3 activated forms , Notch1
IC
and Notch3
IC, whereas Notch2
IC levels were lower than those
of SkMC cells. The activation of Notch signalling was
conﬁrmedbythedetectionof Notch
ICformsofallthreereceptors
in nuclear-enriched fractions (Figure 1b). A speciﬁc anti-
Notch1
IC antibody was used. Moreover, Supplementary Figure
1 identiﬁes Notch3
IC and Notch2
IC bands as decreased in
nuclear-enriched extracts from cell treated with an inhibitor of
g-secretase (i.e., DAPT). In RD cells, both Notch3
IC and Notch2
IC
were detected in cytoplasmic fractions as well, suggesting cell
type-speciﬁc regulation of Notch signalling/trafﬁcking.
16
Consistently, Notch1 and Notch3 were transcriptionally
upregulated in all tumour cell lines whereas Notch2 mRNA
level was only modestly increased in three tumour cell lines,
that is, embryonal RH18 and A204 and alveolar RH41
(Figure 1c). In agreement with Sang et al.,
13 the Notch target
gene HES1 was signiﬁcantly upregulated in all RMS cell lines.
Notch ligand Jagged1 was overexpressed with different
extents (Figures 1a and b) whereas Delta1 and Notch4
IC
were under the threshold of detection in both control and RMS
cells (data not shown). These ﬁndings suggest that Notch1
and Notch3 signalling could be deregulated in RMS cell lines,
irrespective of their subtype.
Notch3 silencing induces myogenic differentiation of
RMS cells. Murine and human myoblasts have been shown
to lose the ability to undergo skeletal muscle differentiation
when Notch3 is activated; conversely Notch3 downregulation
preserves this differentiation potential.
17 Therefore, we focus
on Notch3 to evaluate whether it could be involved in the
inability of RMS cells to terminally differentiate. To this end,
Notch3 was silenced and in vitro RMS cell differentiation was
monitored. As shown in Figures 2a, b and c, numerous
multinucleated ﬁbres were detected in Notch3 siRNA-
transfected RD and RH30 cell lines along with de novo
expression of MHC and troponin, consistent with myotube
fusion. This effect was associated with an increase of the
muscle marker Myogenin in both cell lines (Figure 2d, right
panel). Moreover, Notch3 silencing resulted in enhanced
phosphorylation of p38 MAPK and serine-threonine kinase
Akt, both essential for terminal muscle differentiation
18–20
(Figure 2d, right panel). Consistently, also the Akt down-
stream target serine-threonine kinase mTOR (mammalian
target of Rapamycin) was hyper-phosphorylated.
20 Notch3
siRNA efﬁciency was attested by drastic decrease of mRNA
levels (data not shown) and the reduced Notch3
IC and HES1
protein levels in both cell lines (Figure 2d). Silencing Jagged1
by siRNA lowered Notch3
IC and HES1 protein levels,
especially in RD cells, suggesting that Notch3 activation is
due, at least in part, to the binding with this ligand (Figure 2e).
Despite the fact that Notch1 has not been reported
signiﬁcantly overexpressed in RMS primary tumours with
respect to muscle tissue,
15 it appeared activated in RMS cell
lines (Figures 1a and b). To clarify its role in RMS cells
differentiation, we knocked down Notch1 expression and
monitored the induction of myogenesis in RD and RH30 cells.
Forty-eight hours post-Notch1 siRNA, we detected an
increase in Myogenin expression in RD cells (Supplementary
Figure 2a, upper panel). This resulted in the formation of
muscle-like multinucleated myotubes expressing MHC, albeit
more modestly if compared with that obtained after Notch3
downregulation (Supplementary Figures 2b and c). Differently,
neither increase in Myogenin levels nor myotube-like formation
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Cell Death and Differentiationcould be evidenced in Notch1 siRNA-transfected RH30 cells.
Interestingly, a marked downregulation of Myogenin levels was
detected up to 48h after Notch2 silencing, ruling out the
possibility of Notch2 involvement in the inhibition of myogenic
program in RMS (Supplementary Figure 2a, lower panel). This
ﬁnding is consistent with our observation that Notch2 is not
markedly more activated/expressed in RMS tumour cells as
compared with normal skeletal myoblasts (Figures 1a and c).
Notably, protein and transcript levels of HES1 did not show any
decrease after Notch1 siRNA transfection (Supplementary
Figure 2a, upper panel and data not shown). In Notch2 siRNA
cells, HES1 protein levels were slightly increased with no
signiﬁcant changes in mRNA in both cell lines as compared with
control siRNA-treated cells (Supplementary Figure 2a, lower
panel and data not shown). Therefore, a differential regulation of
HES1 by different Notch paralogs is present in RMS.
Altogether, these results suggest that Notch3 expression/
activation is able to prevent the differentiation of both alveolar
and embryonal RMS cells.
Downregulation of Notch3 reduces RMS cell prolifera-
tion and soft-agar colony formation. To evaluate the impact
of Notch3 siRNA-induced differentiation on cell growth rate, cell
proliferation and cell cycle were analyzed. Notch3 knockdown
Figure 1 Upregulation of Notch signaling components in rhabdomyosarcoma (RMS) cell lines. (a, left) Western blotting of Notch1-3 intracellular cleaved domains (IC),
Jagged1, HES1 and b-actin (loading control) in whole-cell lysates from embryonal (ERMS) and alveolar (ARMS) RMS cell lines and normal human myoblasts SkMCs as
control. Arrows indicate the IC domains of Notch1-3. Notch1
IC was detected using the antibody that recognizes only the activated form (cleaved at Val1744). (a, right)
Histograms report densitometric analysis of Notch1
IC (Val1744), Notch2
IC, Notch3
IC, HES1, and Jagged1 bands normalized to b-actin of three independent experiments.
(b) Western blot analysis of nuclear (N) and cytoplasmic (C) -enriched cell fractions of embryonal (ERMS) and alveolar (ARMS) RMS cell lines. Notch1
IC (Val1744), Notch2
IC
and Notch3
IC forms were detected in all cell lines. b-actin and topoisomerase IIb were used as loading controls to discriminate the different cell fractions. (c) mRNA levels
of Notch1-3, HES1 and Jagged1 (real time RT-PCR) were normalized to b-actin levels and expressed as fold increase over control SkMC (black column; 1 arbitrary unit).
Columns, means; Bars, S.D. Results from three independent experiments are shown
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Cell Death and Differentiationmarkedly decreased cell growth in both RD and RH30 cells (by
almost 50% as early as 3 days after transfection when
compared with control siRNA) (Figure 3a). Similar results
were obtained in embryonal A204 and alveolar RH41 cell lines
(Supplementary Figure 3). We also observed that the ability of
Notch3 siRNA-treated cells to form colonies in soft-agar was
signiﬁcantly impaired (Figure 3b). Interestingly, forcing Notch3
activation by ectopic expression of a Notch3
IC in both RD and
RH30 cell lines led to opposite molecular and functional results
(data not shown). These ﬁndings strongly indicate that Notch3
expression promotes proliferation and supports tumourigenic
features of RMS cells in vitro.
Consistently, cell cycle analysis showed that after Notch3
knockdown, about 80% of RMS cells were in G1 phase
compared with only about 45% of control siRNA cells
(Figure 4a). Also the percentage of cells in S phase was
reducedfrom about45%to about10%inboth cell lines. Inline
with this, Notch3 silencing triggered a marked increase of
p21
Cip1 as early as 24h after treatment (Figure 4b). p21
Cip1
mRNA level was not signiﬁcantly changed within 2 days from
Notch3 depletion, ruling out early transcriptional effects (data
not shown). As shown in Figure 4c, Notch3 silencing also
causedan increase of the under-phosphorylated (active) form
of the retinoblastoma tumour suppressor protein (pRb) and of
thephosphataseandtensinhomologdeletedonchromosome
ten (PTEN). Consistent with a slowing down of cell prolifera-
tion, Notch3 siRNA also decreased extracellular signalling-
regulated kinases ERK1/2 phosphorylation in both cell lines
compared with control siRNA. Collectively, these results
suggest that Notch3 stimulates cell cycle progression by
promoting the G1-to-S phase transition, and that it regulates
the ERK pathway in RMS cells.
Figure 2 Notch3 downregulation promotes RMS cell differentiation. (a) RD and RH30 cells cultured in completemedium (i.e., supplemented with 10% of fetal calf serum)
wereanalyzedafter6daysofNotch3orcontrol(CTR)siRNAtreatment.Representativeimmunoﬂuorescenceshowingdenovoexpressionofendogenousmyosinheavychain
(MHC, green) in multinucleated ﬁbers of Notch3 siRNA-transfected RD and RH30 cells (white arrows). Representative of three assays. (b) Western blotting showing de novo
expression ofTroponinIandb-actin(loadingcontrol)inNotch3 siRNARD andRH30cellstreatedas in(a).(c)RepresentativelightmicroscopypicturesofRD andRH30cells
showing elongated multinucleated structures in Notch3 siRNA-treated cells treated as in (a). (d) Western blotting showing levels of Notch3
IC and HES1 (left) and Myogenin
along with the phosphorylation of p38, Akt and mTOR (right) in RD and RH30 cells 24 and 48h after CTR or Notch3 siRNA transfection. b-actin was the loading control.
Representative of three independent experiments. (e) Western blotting showing levels of Notch3
IC and HES1 in RD and RH30 cells 24 and 48h after CTR or Jagged1 siRNA
transfection. b-actin was the loading control. Representative of three independent experiments
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Cell Death and DifferentiationHES1 has a role in Notch3 signalling in RMS cells. In the
attempt to evaluate whether the function of Notch3 in RMS is
mediated, at least in part, by HES1, we performed loss- and
gain-of-function experiments either silencing or forcing the
expression of HES1 in RMS cells. HES1 downregulation by
siRNAs in RD cells led to an enhancement of p21
Cip1 levels
48h after siRNA transfection (Figure 5a). This happened
although HES1 protein levels were modestly decreased 48h
after siRNAs treatment when transcript reduction reached
about 60 and 70% in RD and RH30 cells, respectively,
compared with control siRNA cells (data not shown). HES1
downregulation did not induce any increase in p21
Cip1 and
Myogenin transcript levels up to 48h after knocking down. In
RH30 cells, these molecular modulations were undetectable.
However, after 6 days of HES1 knocking down, multinucleated
ﬁbres positive for MHC were seen in both cell lines compared
with control siRNA cells (Figure 5b). Interestingly, reduction of
HES1 levels in Notch3-depleted cells reinforced all these
Figure 3 Notch3 depletion reduces proliferation and impairsRMS celllines tumourigenic features in vitro.( a) RD and RH30 cells were transfected (t0) with Notch3 siRNA
orcontrol(CTR)siRNA,culturedincompletemedium(i.e.supplementedwith10%offetalcalfserum)andharvestedandcountedattheindicatedtimepoints.*Po0.05;Bars,
SD. (b)2 10
4 RD living cells (evidenced by trypan blue exclusion) were seeded on soft-agar in 35mm petri dishes 48h after transfection with CTR or Notch3 siRNA.
Histogram represents the mean number of colonies per ﬁeld counted under a light inverted microscope 4 weeks after seeding (two independent experiments in triplicate).
At least ﬁve ﬁelds per dish were checked at 100  magniﬁcation. Bars, S.D. **Po0.001
Figure 4 Notch3 downregulation prevents the G1-to-S phase transition in RMS cell lines. (a) RD and RH30 cells were transfected with Notch3 siRNA or control (CTR)
siRNA and, 48h later, stained with 5-ethynyl-20-deoxyuridine (EdU)-Alexa 488/Cell cycle 633 for analysis by ﬂow cytometry gating on living cells. Left, representative
diagrams. Right, the histogram depicts the percentage of control (CTR) or Notch3 siRNA transfected RD and RH30 cells in G1, S and G2 phases. Representative of three
independent experiments in duplicate. (b and c) Western blotting showing expression of p21
Cip1, PTEN and the Ser
380 phophorylated form of PTEN, and pRb along with the
phosphorylationofERK1/2inwhole-cell extractsafterCTRorNotch3siRNAtransfection.Arrows(c)pointtobandscorrespondingto hyper-(upper)andhypo-phosphorylated
(lower) pRb species. b-actin was the loading control
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Cell Death and Differentiationphenomena suggesting that HES1 cooperates with Notch3
signalling to regulate them in RMS.
Then,we infectedRMScells withan adenovirusexpressing
both human HES1 and the GFP protein (AdHES1) 24h after
Notch3 silencing (see Supplementary Figure 3 for infection
efﬁciency detection). A vector expressing only GFP (AdGFP)
was the control vector. As shown in Figure 6a, p21Cip1 and
Myogenin levels were downregulated 48h after overexpression
of HES1 in both Notch3 and control siRNA-treated cell lines
compared with their AdGFP-infected counterparts. However, in
Notch3 knocked down cells levels of both proteins remained
higher than in control siRNA cells suggesting that (i) the
efﬁciency of HES1 overexpression is not sufﬁcient to completely
block these molecular modulations and/or (ii) additional Notch3-
dependent pathways collaborate with HES1.
However, consistent with these results, after normalization
for the percentage of GFP-positive RD and RH30 cell
populations, cell cycle analysis showed an about 10 and
20% increase of the percentage of HES1-overexpressing
cells (AdHES1) in S phase and 22 and 35% in G2 phase
compared with AdGFP control cells, respectively (Figure 6b,
both panels and Supplementary Figure 4).
Notably,RDcellsoverexpressingHES1didnotdifferentiate
6 days after infection (i.e., 7 days after siRNA treatment), as
testiﬁed by the mutual exclusion of GFP and MHC expression
(Figure6c).Instead,asmallnumberofNotch3siRNARH30cells
overexpressing HES1 are still able to differentiate even if they
formed thinner myotubes compared with AdGFP control ones.
These data indicate that HES1 knockdown partially mimics
Notch3 downregulation in RMS cell lines and, coherently, HES1
forcedexpressionpartiallycounteractsNotch3-depletioneffects.
Therefore, they are supportive for a role of HES1 in the
maintenance of Notch3-dependent pro-tumour effects in RMS.
Short-hairpin (sh)RNA-mediated Notch3 reduction
decreases RMS tumour growth rate in vivo. In the attempt
to evaluate whether Notch3 downregulation affects tumour
growth in vivo, RH30 cells were transfected with a GFP-
expressing plasmid encoding an shRNA against Notch3.
In vitro, a 3 weeks transfection with such Notch3 shRNA
resulted in the formation of persistent RH30 multinucleated
GFP-positive cells (Figure 7A, left), where Notch3 activation
was strongly reduced, as assessed in lysates from cells sorted
according to GFP expression (Figure 7A, right). In addition, a
marked decrease in the proliferation rate of Notch3 shRNA cells
compared with control shRNA ones was observed (data not
shown). Then, nude mice were inoculated with suspensions of
RH30 cells containing a sub-population (B40%) of cells
transiently transfected with Notch3 shRNA (Supplementary
Figure 5). The reason for using a mixture of cells is that in
preliminary experiments, when we inoculated mice with 100%
Notch3 shRNA-expressing cells no xenograft growth was
Figure 5 HES1 downregulation in RMS cells induces cell differentiation mimicking the effect of Notch3 knockdown. RD and RH30 cells were transfected with a Notch3
or control (CTR) siRNA, and 24h later they were transfected with a HES1 or control (CTR) siRNA* in complete medium (i.e., supplemented with 10% of fetal calf serum).
(a) Western blotting showing expression of p21
Cip1 and Myogenin 48h after HES1 silencing in whole-cell extracts. (b) Immunoﬂuorescence analysis shows de novo
expression of endogenous myosin heavy chain (MHC, red) in multinucleated ﬁbers of Notch3, HES1 and Notch3 plus HES1 siRNA-transfected RD and RH30 cells after
6 days. Representative images of three assays
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Cell Death and Differentiationobserved within 2 months from the date of injection (data not
shown), thus no tumour growth was measurable. Analysis of
xenografts from cell suspensions containing Notch3 shRNA
(40%)/wild-type (wt) cells B12 days after tumours became
palpable, that is, within the linear growth phase, showed
signiﬁcant reduction of tumour volume as compared with that
obtained by inoculation of control shRNA (B50%)/wt cell
suspensions (Figure 7B). GFP-positive cells and cells
expressing the proliferative marker Ki67 were reduced in
xenografts derived from Notch3 shRNA injected mice
compared with their control shRNA ones (Figures 7C
and D). Western blotting analysis demonstrated reduction
of Notch3 expression in Notch3 shRNA/wt compared with
control shRNA/wt pooled xenograft samples (Figure 7E).
In summary, we have shown that Notch3 knockdown
induces myogenic differentiation and decreases tumourigeni-
city of RMS cells in vitro and in vivo, and that Notch3 controls
cell cycle progression and the ERK and Akt pathways in RMS
cells. Moreover, we have provided evidence that Notch3
effects in RMS cells are mediated, at least in part, by HES1.
Our data indicate that Notch3 is pivotal to the choice between
proliferation and differentiation in RMS cells.
Figure 6 HES1 overexpression in RMS cells abrogates the effects of Notch3 knockdown. RD and RH30 cells were infected with an Adenovirus expressing HES1
(AdHES1) or a control Adenovirus (Ad-GFP) 24h after transfection with CTR or Notch3 siRNAs. (a) Western blotting showing levels of Notch3
IC, HES1, Myogenin and
p21
Cip1 24h and 48h after Adenovirus infection. b-actin and a-tubulin were the loading controls. Representative of three independent experiments. (b) Cell cycle analysis by
propidiumiodideofRDandRH30cells48hafteradenovirusinfectionwithAdHES1andAdGFP.Left,representativediagrams.Right,histogramsdepictthefoldchangeofthe
cell percentage in the different cell cycle phases for AdHES1 versus AdGFP infected RD and RH30 cells, after normalization for the efﬁciency of infection (Supplementary
Figure 3). (c) Immunoﬂuorescence analysis of AdHES1- and AdGFP-infected RD and RH30 cells (GFP, green) with anti-myosin heavy chain (MHC, red) antibody 6 days
after infection. Representative images of three independent experiments
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Cell Death and DifferentiationDiscussion
In this study, we investigated the involvement of Notch
signalling in the inability of RMS cells to complete the
myogenic program. Consistently with data on primary RMS
tumours,
15 we showed that Notch3 is overexpressed in RMS
cell lines and abnormally activated in a ligand-dependent
manner. We also provided evidences that there is a causal
relationshipbetweenNotch3expressionandthetumourigenic
properties of RMS cells in vitro, as Notch3 silencing is
sufﬁcient in restoring myogenesis and inhibiting cell cycle
progression and anchorage-independent growth. Moreover,
Figure 7 Notch3 downregulation in RMS cells reduces tumour growth in vivo.( A) RH-30 cells were transfected with a Notch3 short hairpin (sh)RNA- or control (CTR)
shRNA-GFP-plasmids and images of GFP ﬂuorescence (grey) were acquired after 3 weeks of puromycin selection (Left). Arrows depict nuclei of newly formed myoﬁbers
(200  magniﬁcation). (Right) 48h post-shRNAs transfection, positive GFP was separated from negative GFP cells by cell sorting and expression of Notch3
IC, and b-actin
(loading control) were analyzed by western blotting. Representative of two independent experiments. (B, Left) Mouse-bearing CTR shRNA (as a mixture of control (CTR)
shRNA-GFP/wild-type cells) and Notch3 shRNA (as a mixture of Notch3 shRNA-GFP/wild-type cells) tumour xenografts (black arrows; left ﬂank: a and right ﬂank:
f, respectively). (Middle) xenografts from nude mice injected with Notch3 shRNA RH30 cells (wild-type/Notch3 shRNA cell ratio B60%/40%; f, g, h, i and l). Xenografts from
CTR shRNA cells (wild-type/CTR shRNA cell ratio B50%/50%; a, b, c, d and e) were controls. (Right) Histogram reports tumour volumes of each xenograft. (C, Left)
Haematoxylin/eosin staining and immunolabeling of Ki67 and GFP of 5mm serial sections from xenografts of mice injected with CTR shRNA and Notch3 shRNA RH30 cells
(from d and i samples) (400  magniﬁcation). GFP right panels are a higher magniﬁcation of left panels (600  magniﬁcation). Representative of three xenografts per condition.
(D) Histogram depicts the average of the percentage of GFP-positive cells per ﬁeld in ﬁve ﬁelds per tumour section. Bars,S . D .* Po0.05. (E) The expression of Notch3
IC was
analysed by western blotting in lysates of samples from mice injected with CTR shRNA and Notch3 shRNA RH30 cell suspensions (three xenografts were pooled per group)
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Cell Death and Differentiationlowering Notch3 expression, even only in a fraction of cells,
decreased tumour growth in vivo.
All these observations are consistent with recent studies
demonstrating that (i) Notch3 is highly expressed in the most
immature subpopulation of satellite stem cells that gives rise
to skeletal muscle-committed precursors,
21 (ii) the expression
of Notch3 in satellite cells is mutually exclusive with that of
early skeletal muscle markers such as MyoD and Myogen-
in,
21,22 (iii) the expression of Notch3 in proliferating myoblasts
is lost during the induction of differentiation
22 and, conversely,
(iv) the induction of Notch3 expression in myoblasts correlates
with the loss of skeletal muscle features blocking myogenesis.
17
In vitro Notch3 knockdown resulted in both alveolar and
embryonal cells in an early signiﬁcant overexpression of the
p21
Cip1 protein, along with an increase of Myogenin and
the hypo-phosphorylated form of pRb, as reported during
physiological skeletal muscle differentiation.
23,24 Interestingly,
alveolar cells showed lower induction of p21
Cip1 and needed
sustained levels of Notch3 silencing compared with embryonal
ones. Consistent with the notorious context-dependence of
Notch signalling, this ﬁnding is possibly related to high Notch1
and/or fusion proteins expression in alveolar RMS.
25
Notch3 knockdown also increased phosphorylation of p38
MAPK, previously shown to be inhibited by Notch in
myoblasts,
26 Akt and Akt-target mTOR, which all cooperate
to myogenesis.
18–20,23,27 Although the difference between the
molecular mechanisms underlying Akt/mTOR-dependent
mitogenesis or myogenesis in RMS needs to be fully
elucidated,theseresultsprovideinsightsonNotch-Akt/mTOR
pathway cross-talk in this soft-tissue sarcoma suggesting
potential therapeutic applications.
28 We also noticed an
increase in PTEN, reported to be regulated by Notch pathway
in several cancer types,
29,30 and that might act as a negative
feedback associated with prolonged Akt activation.
31 How-
ever, the concomitant increase in the less active Ser
380-
phosphorylated PTEN form could control the PTEN-PI3K-Akt
axis to avoid suppression of the myogenic process.
32
Notably, Notch3 depletion was consistently associated with
strong inhibition of HES1 expression, suggesting that Notch3
regulation of RMS cells differentiation and proliferation
occurs, at least in part, through HES1. Indeed, (i) forcing the
HES1expression in Notch3 knockeddownRMS cellspartially
overcame, whereas (ii) co-downregulation of Notch3 and
HES1 facilitated Notch3-depletion effects. These observa-
tions demonstrate that HES1 lowering is necessary for
the Notch3 silencing-dependent anti-proliferative and pro-
myogenic effects, and support HES1 as a downstream
effector of Notch3 signalling in RMS.
This feature is speciﬁc of the Notch3 paralog as neither the
downregulation of Notch1, also overexpressed and activated
in RMS cell lines compared with myoblasts, nor that of Notch2
resulted in HES1 protein level reduction.
Such differential effects of Notch receptors have been
reported in several types of cancer and appear context-
dependent. Amongthese, in breastcancer, medulloblastoma,
multiple myeloma and mesothelioma, some Notch paralogs
have an oncogenic role whereas others behave as tumour
suppressors modulating differentially downstream targets.
33
The mechanism regulating these differential functions is
under intense investigation and could be related to a diverse
transcriptional activitybut alsototheability tobindthe RBP-jk/
CBF-1 complex and/or to displace corepressors from the
transcriptional complex.
14
Increasing evidence suggests that oncogenesis in RMS
involves multistage dysregulation of several signalling pro-
teins.
34 It is likely that other pathways cross-talk with
Notch3 during RMS development. The cross-talk of different
Notch-receptors pathways in tumours has been previously
reported.
35 In this regard, we cannot exclude that Notch1
cooperates with Notch3, at least in the embryonal cells.
However, recent data showed no signiﬁcant differences in the
expression of Notch1 mRNA levels in primary RMS tumours
compared with normal muscle tissues,
15 suggesting that this
Notch paralog could have a minor role in RMS pathogenesis.
In this regard, it is conceivable that Notch1 upregulation in
RMS cell lines could be ascribed to the molecular features of
tumour tissues from which these cells derive. On the basis of
this possibility, in RMS tumours with high Notch1 expression/
activation, Notch1 and Notch3 signalling pathways could
cooperate to sustain the tumourigenic phenotype.
Strikingly, Myogenin expression was severely impaired
after Notch2 downregulation in RMS cell lines. This observa-
tion is consistent with ﬁndings showing similar Notch2 mRNA
and activation levels in RMS cell lines as compared with
normal myoblasts, and with the evidence that Notch receptors
can have differential and even opposite roles in the same type
of cancer.
30 Future studies could dissect the speciﬁc role of
each Notch paralog in RMS and Notch3-dependent direct and
indirect effects.
Accordingly to the in vitro results, after injection of tumour
cells(i.e.,2 10
6cellsperinjection),wenoticedthatxenografts
formed by the cell population including Notch3 shRNA cells
grew more slowly compared with control ones. Moreover, the
lowerpercentageofGFP-positivecellsfoundinNotch3shRNA/
wt xenograftssuggests thattheyresulted mostly from wild-type
untrasfected cells with respect to control shRNA/wt ones. The
evidence that xenografts containing Notch3-depleted popula-
tion showed GFP cellsthatremainviable couldbe explainedby
the polyclonal character of the injected cell population, in which
the level of Notch3 knockdown was heterogeneous and,
possibly, in certain cells could not be sufﬁcient to block cell
engraftment and proliferation. However, Notch3 downregula-
tion even in a fraction of cells affects the in vivo growth of
alveolar RMS cells that are highly resistant to treatments.
Altogether, these results offer new insights into the
deregulation of the myogenic program in the pathological
context of RMS. Our results appear also relevant under a
clinical translational point of view, as increasing evidence
point out on the identiﬁcation of small molecules and inhibitors
speciﬁc to each Notch receptor.
36 Notch3-selective inhibition,
as reported for a preclinical model of lung cancer,
37 could be,
therefore, evaluated as potential adjuvant strategy in the
treatment of chemotherapy-resistant RMS. Notch3-targeted
therapy could potentially reduce possible toxic effects of
complete Notch signalling pathway blockade.
37
In conclusion, our data identify Notch3 as an inducer of the
dysregulated differentiative program in RMS providing evi-
dence that its blockade restores myogenesis and prevents
tumourigenic potential of tumour cells, thus suggesting novel
therapeutic approaches.
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Cell Death and DifferentiationMaterials and Methods
Cell lines. RH30 (alveolar RMS, ARMS) and RD (embryonal RMS, ERMS) cell
lines were obtained from American Type Culture Collection (Rockville, MD, USA).
RH41 (ARMS), A204 and RH18 (ERMS) cell lines were obtained from Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig,
Germany). Normal Human Skeletal Muscle cells (SkMC; myoblasts) were
obtained from PromoCell (Heidelberg, Germany). Supplementary Methods report
cell lines and culture details.
Western blotting. Western blotting was performed on whole-cell lysates as
previously described.
38 See Supplementary Methods for antibodies and additional
details.
Nuclear fraction-enrichment. Cells were lysed in cytoplasm lysis buffer A
(10mM HEPES pH 7.9, 10mM KCl, 0.2mM EDTA and 1mM DTT), containing
protease inhibitors, 0.5mM phenylmethylsulfonylﬂuoride (PMSF) and 0.6% Nonidet
P-40 (Sigma Chemical Co., St. Louis, MO, USA). Lysates were centrifuged at
10000r.p.m. for 10min at 41C, and the supernatants (cytoplasmic fractions) were
split into aliquots and rapidly frozen. The nuclear pellet was washed in buffer A
without Nonidet P-40 and ﬁnally resuspended in nuclear lysis buffer B (20mM
HEPESpH7.9,0.4MNaCl,2mMEDTA,1mMDTT),containingproteaseinhibitors
and 1mM PMSF (Sigma Chemical Co.). Samples were incubated on ice for 30min
and centrifuged at 13000r.p.m. for 10min at 41C; the supernatants (nuclear
fractions) were split into aliquots and rapidly frozen. The remaining pellets,
containing DNA as well as proteins tightly associated with DNA, were washed in
reticulocyte buffered buffer (RSB: 10mM NaCl, 10mM Tris-HCl pH 7.5 and 1.5mM
MgCl2)and ﬁnally resuspended in RSB andHCl 0.4N to obtain HCl-soluble proteins
(Castiglia et al., Neurochem Res (1994); Cestelli et al., Cell Mol Neurobiol. 1992).
Thesamples wereincubatedat least1h at 41C and centrifugedat 10000r.p.m. for
20min at 41C. The acid-soluble proteins were recovered from the supernatants by
precipitation with 10 volumes of acetone at  201C and centrifugation at
10000r.p.m. for 20min at 41C. HCl-soluble proteins were ﬁnally resuspended in
distilled water, split into aliquots and frozen.
Cleaved Notch1 (Val
1744) was obtained from Cell Signaling (Beverly, MA, USA)
and the anti-acetyl-Histone H3 was obtained from Millipore (Temecula, CA, USA).
The other antibodies were already described in the revised version of the
manuscript.
Real time RT-PCR. Total RNA was extracted using TRizol (Invitrogen,
Carlsbad, CA, USA) and analyzed by real-time RT-PCR as described.
39 See
Supplementary Methods for primer sequences and details.
Transient RNA interference. Cells were transfected with double-stranded
synthetic 21-mer RNA oligonucleotides (siRNA) against Notch3 (Hs01_00101285;
Sigma Chemical Co.) or ﬂuorescein-labeled non-targeting siRNA control (100nM ﬁnal
concentration) using Oligofectamine (Invitrogen) according to manufacturer’s
recommendations. The efﬁcacy of siRNA transfection was assessed by visualization
of ﬂuorescent cells under an Eclipse TE200 microscope (Nikon, Sesto Fiorentino,
Firenze, Italia) and images were acquired through Metamorph software version 7.1
(Crisel, Roma, Italia). JAG1 silencing was performed at 100nM (ﬁnal concentration)
usingSilencerSelectsiRNAreagents(Appliedbiosystems,CA,USA/Ambion,TX,USA).
ON-TARGETplus SMART pool siRNA (Thermo Fisher Scientiﬁc, Lafayette,
CO, USA), were used for downregulating HES1.
Immunoﬂuorescence. Immunoﬂuorescence for visualizing MHC was
performed as previously described
38 using the MF-20 antibody (Developmental
StudiesHybridoma Bank at the Universityof Iowa, Iowa City, IA, USA). Brieﬂy, cells
were washed three times in PBS, ﬁxed for 10min in 4% PFA and permealized for
5min with 0.2% Triton X-100 in PBS. After 30min in PBS containing 3% bovine
serum albumin, slides were incubated for 1h at room temperature with the MF-20
antibody against myosin heavy chain (MHC; DSHB, USA). After two washing in
PBS, cells were treated with a ﬂuorescein-linked secondary antibody. After being
stained for 2min with 200ng/ml DAPI in PBS, chamber slides were mounted in
GelMount (Biomeda, Foster City, CA, USA). Images were acquired with an Eclipse
E600 ﬂuorescence microscope,throughLUCIAsoftwareversion4.81(Nikon,Sesto
Fiorentino, Firenze, Italy).
Cell proliferation and cell cycle assay. Cells were transfected at 24h
after seeding (Day 0) with siRNAs, harvested and counted at the reported time
points. For cell cycle assay, the 5-ethynyl-20-deoxyuridine (EdU) incorporation was
performed using Click-iT EdU Flow Cytometry assay Kit (Invitrogen), and cells were
analyzed with ﬂow cytometry using a FACSCantoII and a FACSDiva 6.1 software
(BD Biosciences, San Jose `, CA, USA). For adenoviruses infections, GFP-positive
cells’ cell cycle was evaluated using propidium iodide staining and ﬂow cytometry
(FCM) analysis. Cells were harvested by trypsinization, washed in cold phosphate
buffered saline (PBS) 1 , ﬁxed in 50% PBS and 50% acetone/methanol (1:4 v/v)
for at least 1h, and, after removing alcoholic ﬁxative, stained with a solution
containing 50mg/ml PI and 100mg/ml RNase (Sigma Chemical Co.) for 30min at
room temperature, in dark. Samples were then measured by using a FACScan
cytoﬂuorimeter. Twenty thousand events per sample were acquired.
Soft-agar colony formation assay. After 48h of transfection with Notch3
siRNA or control siRNA, RMS cells were assayed for their capacity to form colonies
in soft-agar as previously described.
38 Brieﬂy, a total of 2 10
4 or 3 10
4 cells
were suspended in DMEM (10% FCS) containing 0.35% Noble agar (Sigma
Chemical Co.). Cells were plated on a layer of 0.7% Noble agar in DMEM (10%
FCS)onto a 35-mmpetri dish. Mediumwas refreshedevery5 days.On week 4, the
number of colonies per ﬁeld was counted under the contrast-phase Eclipse E600
microscope (Nikon). Two independent experiments were carried out in triplicate.
Adenovirus infection. A recombinant, replication-deﬁcient adenoviral CMV
bicistronic vector expressing both human HES1 (AdHES1) and the green
ﬂuorescent protein (GFP) (a gift of GP Dotto) was used to infect RD and RH30
cells (100 plaque-form units per cell) as described.
40 A vector expressing only the
reporter gene GFP (AdGFP)(a gift of G Toietta) was used as control. The efﬁciency
ofinfectionwasdeterminedanalysingthepercentageofGFP-positivecellswithﬂow
cytometry using a FACSCantoII and a FACSDiva 6.1 software (BD Biosciences).
Prolonged RNA interference with shRNA and cell sorting. Short
hairpin RNA (sh)RNA-mediated silencing was performed by transfecting cells with a
pGFP-V-RS vector expressing 29 nucleotide shRNAs against Notch3 and a green
ﬂuorescent protein (GFP) as reporter gene (TG311139: Notch3 target sequence
50-GTGAGAGCTGCAGAATATCGATGAC-30; Origene, Rockville, MD, USA) using
Lipofectamine 2000 (Invitrogen). A non-targeting shRNA was used as control. Notch3
silencing was assessed by western blotting after cell sorting and 48h after transfection.
Living cells identiﬁed by Forward and Side Scatters light were sorted as GFP-positive
and GFP-negative populations by a FACSAriaII and with a FACS DIVA 6.1 software
(BD Biosciences). After 3 weeks of selection with puromycin (1mg/ml), images of
ﬂuorescent cells were acquired under an Eclipse TE200 ﬂuorescence microscope
(Nikon) through Metamorph software version 7.1 (Crisel, Roma, Italia).
Xenograft experiments. Athymic 6-week-old female BALB/c nude mice
(nu
þ\nu
þ) were purchased from Charles River (23885 Calco (Lecco), Italy).
Procedures involving animals and their care were conformed to institutional guidelines
that comply with national and international laws and policies (EEC Council Directive
86\609, OJ L 358, 12 December 1987). RH30 cells transfected with Notch3 or CTR
shRNA plasmids were transfected again 24h later and allowed to grow for additional
24h. The efﬁciency of transfectionwas determined by ﬂowcytometry at this time. Cells
(2 10
6) were injected subcutaneously into the posterior ﬂanks of nude mice in a cold
mixture of PBS\Matrigel (ratio 1:1). At 2 weeks after the tumours became palpable,
mice were sacriﬁced, xenografts were removed and tumour volume was measured as
described.
35 Western blotting on total lysates from RMS xenografts were performed by
pulling three Notch3 or CTR shRNA-derived specimens from snap frozen tissues.
Immunohistochemistry of xenograft samples. Serial 5mm sections
from parafﬁn-embedded tumours and control tissues were deparafﬁnized and
antigen retrieval was performed for 25min at 981C with citrate pH6. After
endogenous peroxidase blocking at room temperature (RT), 3–5% BSA or 5% goat
serum in Tris-buffered saline was applied for non-speciﬁc site blocking. Additional
blocking was performed using Biotin Blocking System (DAKO Carpintera, CA,
USA).Sectionswereincubatedwithanti-GFP(Clontech,MountainView,CA,USA),
anti-Ki67 (Novocastra Laboratories Ltd, Newcastle upon Tyne, UK) antibodies and
the appropriate secondary antibodies. Positive reactions were visualized by
incubation with diaminobenzidine (DAB chromogen kit, DAKO Carpinteria, CA,
USA). Negative controls were done by treating serial cross-sections simultaneously
with isotype non-speciﬁc IgG or omitting the primary antibody. Section were then
dehydrated and mounted in non-aqueous mounting medium. Levels of GFP
expression were semi-quantitatively quantiﬁed at 400  magniﬁcation by scoring
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Scoring was done by two blinded independent observers. Sections were scored
using an Eclipse E600 microscope (Nikon). Images were acquired through LUCIA
software, version 4.81 (Nikon) with a Nikon Digital Camera DXM1200F.
Statistical analysis. Continuous variables were analyzed by Mann-Whitney
U-test or Kruskal-Wallis test for pairwise or multiple comparisons, respectively.
Statistical signiﬁcance was set at a two-tailed P-value o0.05. All analyses were
performed with SPSS 11.5.1 for Windows Package (SPSS, Inc., 1989–2002 and
LEADTOOLS 1991–2000, LEAD Technologies Inc., Berks, UK).
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